EFTR Research and Charts

EFTR - eFFECTOR Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-03-27)

Last 0.00	Change ⇓ 0.00 (0.00%)	Volume 201
	Open 0.00	High 0.00	Low 0.00

8EMA (Daily) 0.00	40EMA (Daily) 0.00	50EMA (Daily) 0.00	STO (Daily) 0.000	MACD Hist (Daily) 0.000
8EMA (Weekly) 0.000	40EMA (Weekly) 1.19	50EMA (Weekly) 2.16	STO (Weekly) 0.000	MACD Hist (Weekly) 0.305


Company Profile
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT, and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.